First-in-human Phase 1 Study of ML261 in R/R SCLC and NECs Initiated by Moonlight Bio
Moonlight Bio has initiated a first-in-human Phase 1 trial for ML261, targeting R/R SCLC and select NECs.
Asset / Drug
Drug and asset intelligence for ML261 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
CAR T Cell Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.